BACKGROUND & AIMS:
Celiac disease (CeD) is a prevalent autoimmune condition. Recurrent signs and symptoms are common despite treatment with a gluten-free diet (GFD), yet no approved or proven nondietary treatment is available. METHODS: In this multicenter, randomized, double-blind, placebo-controlled study, we assessed larazotide acetate 0.5, 1, or 2 mg 3 times daily to relieve ongoing symptoms in 342 adults with CeD who had been on a GFD for 12 months or longer and maintained their current GFD during the study. The study included a 4-week placebo run-in, 12 weeks of treatment, and a 4-week placebo run-out phase. The primary end point was the difference in average on-treatment Celiac Disease Gastrointestinal Symptom Rating Scale score. RESULTS: The primary end point was met with the 0.5-mg dose of larazotide acetate, with fewer symptoms compared with placebo by modified intention to treat (n ¼ 340) (analysis of covariance, P ¼ .022; mixed model for repeated measures, P ¼ .005). The 0.5-mg dose showed an effect on exploratory end points including a 26% decrease in celiac disease patient-reported outcome symptomatic days (P ¼ .017), a 31% increase in improved symptom days (P ¼ .034), a 50% or more reduction from baseline of the weekly average abdominal pain score for 6 or more of 12 weeks of treatment (P ¼ .022), and a decrease in the nongastrointestinal symptoms of headache and tiredness (P ¼ .010). The 1-and 2-mg doses were no different than placebo for any end point. Safety was comparable with placebo. CONCLUSIONS: Larazotide acetate 0.5 mg reduced signs and symptoms in CeD patients on a GFD better than a GFD alone. Although results were mixed, this study was a successful trial of a novel therapeutic agent targeting tight junction regulation in patients with CeD who are symptomatic despite a GFD. Clinicaltrials.gov: NCT01396213.
Keywords: Celiac Disease; Gluten; Therapeutic; Tight Junction. C eliac disease (CeD), a genetic autoimmune condition, affects approximately 1% of the Western population. 1, 2 CeD is triggered by ingestion of gluten-containing foods and managed by a gluten-free diet (GFD). 3, 4 Recurrent CeD signs and symptoms resulting from inadvertent or deliberate gluten exposure have been reported in approximately 70% of CeD patients on a GFD. 5, 6 Although persistent symptoms may have a variety of causes, one potential source is sporadic gluten exposure, 7 which may contribute to persistent enteropathy, continued symptoms, and reduced quality of life.
In CeD, paracellular permeability is increased by an inflammatory response to gluten entry into the intestinal mucosa. 8 Increased permeability promotes gluten peptide transport to gut-associated lymphoid tissue, initiating inflammatory cytokine release and T-cell recruitment. [8] [9] [10] An intestinal permeability-inflammation loop is established, leading to a multitude of gastrointestinal and systemic manifestations.
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Larazotide acetate is a novel, locally acting, nonsystemic, synthetic, 8-amino acid oral peptide, discovered during functional screening of synthetic Vibrio cholera-related peptides. Larazotide acetate is a first-in-class tight junction (TJ) regulator under development as an adjunct to a GFD. Larazotide acetate appears to prevent opening of intestinal TJs by promoting TJ assembly and actin filament rearrangement, which prevents gluten from reaching the intestinal submucosa and triggering an inflammatory response (Supplementary Figure 2) . 8, 12 Nonclinical studies with larazotide acetate have shown proof-of-concept of TJ regulation including the inhibition of gliadin-induced TJ alteration, macrophage recruitment, and increases in intestinal permeability. 8, 12, 13 In 4 prior clinical trials, larazotide acetate showed a safety profile comparable with placebo. [14] [15] [16] In initial clinical trials using gluten challenge, larazotide acetate prevented gluten-induced symptoms and blunted increases in anti-tissue transglutaminase (tTG) antibodies, interferon-g, and intestinal permeability. [14] [15] [16] These results provided the foundation for the current phase IIb study.
Despite being a common condition that often responds incompletely to GFD, there is currently no approved nondietary treatment for CeD. 17, 18 This multicenter, randomized, placebo-controlled trial was a large clinical trial conducted in CeD patients and was designed to assess the efficacy and safety of larazotide acetate as an adjunct to a GFD in adult patients with persistent symptoms despite maintenance of a long-term GFD. A secondary objective was to validate the Celiac Disease Patient-Reported Outcome (CeD PRO) instrument as a daily measure of therapeutic effects.
Materials and Methods
The protocol was approved by relevant institutional review boards. Patients provided written informed consent, the study was conducted according to Good Clinical Practice, and was registered on Clinicaltrials.gov (NCT01396213).
Patients
Entry criteria were as follows: age 18-75 years, body mass index (BMI) of 16-45 kg/m 2 , CeD confirmed by intestinal biopsy or capsule endoscopy (capsule endoscopy was the entry criteria for 7 of 342 patients randomized) plus positive serology 12 months before study entry, maintenance of a GFD for 12 or more consecutive months before screening, and adherence to current GFD on study. Underweight patients (BMI, 16-18.5 kg/m 2 ) were included because these patients were believed by the investigators to reflect patients who were underweight as a result of active celiac disease and thus would be most likely to benefit from therapy underweight due to active celiac disease and thus would be likely to benefit from therapy while not at increased risk of complications of severe malabsorption owing to severe malabsorption or other conditions. All celiac serologies were performed centrally using the INOVA (San Diego, CA) QuantaFlash assay at Mayo Clinical Laboratories. The cut-off value for levels that were positive for tTG IgA and IgG were 4.0 and 6.0, respectively. The cut-off value for levels that were for positive deamidated gliadin peptide (DGP) IgA and IgG were 20. To evaluate study-related changes in serologic titers, patients with undetectable anti-tTG and anti-DGP antibody levels were excluded. Patients experienced at least 1 gluten-related symptom (diarrhea, abdominal pain, bloating, nausea) in the month before screening, and at screening were required to have a qualifying score of 2 or higher, reflecting "mild discomfort" on the CeD domains of the Gastrointestinal Symptom Rating Scale 19 (CeD-GSRS). The GSRS and CeD-GSRS, which contains 10 items from the GSRS, diarrhea, abdominal pain, and indigestion domains (Supplementary Appendix A), have been used in multiple trials of CeD 14, [20] [21] [22] and other gastrointestinal (GI) disorders. 23, 24 All survey data were collected daily from patients using an electronic clinical outcome assessment data collection device (Bracket Global, Wayne, PA).
Exclusion criteria included refractory CeD, severe CeD complications (eg, enteropathy-associated T-cell lymphoma), other chronic inflammatory GI disease (eg, inflammatory bowel disease), diabetes, or autoimmune, psychiatric, or neurologic disease that could interfere with assessments. Smoking, pregnancy or breastfeeding, previous exposure to larazotide acetate, concomitant use of systemic or intestinal immune suppressants, continuous antibiotics, nonsteroidal anti-inflammatory drugs, and medications that alter gastric pH or intestinal permeability were prohibited.
Study Design and Procedures
This 20-week study was conducted in 3 phases: a 4-week single-blind placebo run-in phase, a 12-week double-blind treatment phase, and a 4-week placebo run-out phase Randomization and masking. Patients were stratified into 4 groups according to sex (85%:15%, female:male) and baseline CeD-GSRS scores (<3 or 3). Randomization was performed using permuted-block randomization and was kept confidential until the study was unblinded. Randomization was 1:1:1:1 to larazotide acetate 0.5-mg, 1-mg, or 2-mg capsules, or placebo in identical capsules.
After the 4-week placebo run-in, study drugs were selfadministered 3 times daily, 15 minutes before meals. Patients returned unused capsules for drug compliance assessment.
Blood was collected at visits 2, 4, 6, and 7, or early termination for chemistry, hematology, anti-tTG, and anti-DGP antibodies.
Patients rated CeD symptoms daily on the CeD PRO and weekly with the CeD-GSRS. The CeD PRO developed by the sponsor in accordance with the US Food and Drug Administration's Study Endpoints and Labeling Development guidelines 25 initially was validated in this trial (Supplementary Appendix B). Patients completed the CeD PRO using an electronic clinical outcome assessment data collection device. Responses were scored on an 11-point Likert scale (range, 0-10), with higher scores indicating greater symptom severity. Results represent averages for each item in a domain or subdomain, aggregated over a 7-day period.
End Point Measures
The primary end point was the difference in average weekly on-treatment CeD-GSRS score for each dose vs placebo, over the 12-week active treatment period. The CeD-GSRS captures treatment effect over time in this disease characterized by chronic and variable flares with episodic symptoms. 14, 20, 26 Symptom improvement was chosen as a primary end point in accordance with regulatory guidance. 25 Secondary end points were a change from baseline in CeD-GSRS score, average weekly on-treatment score, and a change from baseline in both the CeD PRO GI and abdominal domain scores.
Exploratory end points included average weekly ontreatment differences in total and individual GSRS domain scores; number of patients experiencing a 50% or more reduction from the baseline weekly average CeD PRO abdominal domain scores for 6 or more of 12 weeks; average ontreatment weekly number of bowel movements and stool consistency measured using the Bristol Stool Form Scale; average on-treatment weekly number of CeD PRO GI symptomatic days, defined as the mean CeD PRO abdominal domain scores of 3 or higher, or diarrhea and loose stool domain score of 3 or higher; average on-treatment weekly number of improved symptom days, defined as the mean CeD PRO abdominal domain scores of 1.5 or less, and diarrhea and loose stool domain score of 1.5 or less; CeD PRO non-GI domain (headache and tiredness) scores; and changes in anti-tTG and anti-DGP antibody levels over the treatment phase.
GFD compliance was assessed using the Gluten-Free Diet Compliance Questionnaire (Supplementary Appendix C), administered at week 16 and assessed voluntary and/or inadvertently ingested gluten on-study.
Safety assessments included the frequency and severity of treatment-emergent adverse events (AEs), serious AEs, clinical laboratory parameters (hematology, chemistry, urinalysis) (Supplementary Table 1) , electrocardiograms, and vital signs.
Statistical Analyses
Estimates for treatment effect and variability of changes from baseline in CeD-GSRS scores in the CLIN1001-006 study 14 were used to determine sample size. Based on a SD of s ¼ 0.548 and a type 1 error rate of a ¼ .05, and assuming a 14% drop-out rate, 80 subjects per treatment group (320 total) would provide 80% power to detect a 0.3-point change from baseline difference in the CeD-GSRS score between larazotide acetate doses and placebo.
Efficacy analyses included all patients receiving 1 or more doses of study drug during double-blind treatment and had 1 or more postbaseline assessment (modified intent-to-treat population). Efficacy results for larazotide acetate doses were compared independently with placebo. An analysis of covariance (ANCOVA) was used for the primary, secondary, and exploratory end points related to GSRS, CeD-GSRS, and CeD PRO scores, with treatment, sex, baseline CeD-GSRS randomization stratum, and randomization cohort as fixed effects, and baseline score as a covariate. Sensitivity analyses were conducted using a mixed model for repeated measures (MMRM). MMRM analyses included treatment and study week as main effects, sex, baseline CeD-GSRS randomization stratum, randomization cohort, and baseline score as covariates, and weekly CeD PRO scores as repeated measures. Baseline score was the last nonmissing observation before the first dose of investigational drug. The proportion of patients with a 50% or greater reduction from the baseline CeD PRO abdominal domain scores for 6 or more of 12 weeks was assessed using the Cochrane-Mantel-Haenszel test for between-treatment comparison, stratified by sex, baseline CeD-GSRS, randomization stratum, and randomization cohort.
Safety assessments were performed for all patients who received 1 or more doses of study drug.
Role of the Funding Source
The principal investigator and leading co-investigators designed the study in collaboration with Alba Therapeutics Corporation and Cephalon/Teva, conducted the study, and provided oversight for data collection. Statistical analysis including sensitivity analysis was designed jointly a priori by the authors and Alba Therapeutics. Data analysis was performed by Chao Wang, PhD, and John Han, PhD, of PharmaData Associates, funded by Alba and Cephalon/Teva. All authors contributed to data interpretation and writing and editing the manuscript. Drs. Leffler and Murray had full access to all study data, contributed equally to manuscript preparation, and had final responsibility for the publication.
Results

Study Population
This study was conducted at 74 North American sites. A total of 783 patients were screened and 454 participants entered the placebo run-in phase (Supplementary Figure 1) . At the end of the placebo run-in phase, 342 patients were randomized to receive placebo (n ¼ 84), or larazotide acetate 0.5 mg (n ¼ 86), 1 mg (n ¼ 85), or 2 mg (n ¼ 87) 3 times per day. Two randomized patients were lost to follow-up evaluation before receiving the drug, leaving 340 patients for modified intent-to-treat analysis. The discontinuation rate during double-blind treatment was consistent across treatment groups (11 patients per arm), most frequently owing to AEs (n ¼ 18) (Supplementary  Table 2 ) or unwillingness to participate (n ¼ 14). The mean treatment duration for all patients was 80 days (SD, 15.5 days). Patient characteristics were similar across treatment groups (Table 1) .
Patients reported multiple CeD symptoms during the placebo run-in phase: 97% reported gas, 92% reported bloating, 79% reported abdominal cramping, 80% reported pain, and 67% reported loose stools. Constipation, nausea, diarrhea, and vomiting were reported by 57%, 50%, 44%, and 4% of patients, respectively. Non-GI symptoms, headache and tiredness, each were reported by 70% of patients.
Efficacy
Primary end point. The primary end point, improved average on-treatment CeD-GSRS score vs placebo, was met at the 0.5-mg larazotide acetate dose (ANCOVA, P ¼ .022; MMRM, P ¼ .005), but not for the 1-mg or 2-mg doses (Table 2) . Consistent with prior studies, 14 the mean CeD-GSRS scores trended down during the placebo run-in phase and then increased at week 0 when patients not meeting the mean weekly CeD-GSRS score eligibility threshold were discontinued (Figure 1 ). Symptomatic improvement with larazotide acetate 0.5 mg was evident by treatment week 2 and was sustained over the 12-week treatment period. Higher larazotide acetate doses were not significantly different from placebo. Per-protocol results were similar for the primary end points with an improved average on-treatment CeD-GSRS score vs placebo at the 0.5-mg larazotide acetate dose (ANCOVA, P ¼ .007; MMRM, P ¼ .001). Similarly, results remained significant after adjustment for both age (ANCOVA, 0.020; MMRM, 0.005) and BMI (ANCOVA, 0.017; MMRM, 0.004).
Secondary end points. Numeric differences in favor of larazotide acetate 0.5 mg were observed in average ontreatment scores, although not all achieved statistical significance (Table 2 ). Improvement from baseline in the mean CeD-GSRS score was greater in the larazotide acetate 0.5-mg group (MMRM, P ¼ .041). Average on-treatment scores and changes from baseline scores in the CeD PRO abdominal and GI domains favored the 0.5-mg treatment arm but were not statistically significant. No significant improvements were noted for any secondary end point at higher larazotide acetate doses. Exploratory end points. Exploratory end points also supported the effectiveness of 0.5-mg larazotide acetate 3 times per day ( Table 2 ). The average on-treatment total GSRS score decreased in the 0.5-mg larazotide acetate group vs placebo (ANCOVA, P ¼ .017; MMRM, P ¼ .004). The average on-treatment CeD PRO non-GI domain scores for headache and tiredness also were lower in the 0.5-mg larazotide acetate group (ANCOVA, NS; MMRM, P ¼ .010) (Supplementary Figure 1) .
Patients receiving 0.5 mg larazotide acetate had 26% fewer CeD PRO GI symptomatic days (defined a priori as a day with a mean score of 3 on either the abdominal (Figure 2 ), indicating reductions of 0.56 days/wk, and an overall reduction of 6.72 symptomatic days over the treatment period vs placebo. This finding was accentuated in a subanalysis of patients with 3 or more symptomatic days per week at baseline (n ¼ 60). In this cohort, there was a reduction of 1.89 days per week in the 0.5-mg arm compared with 0.58 days/wk in the placebo arm, a net decrease of 15.72 fewer symptomatic days during the 12 weeks of treatment. Similarly, in the 0.5-mg larazotide arm there was a 31% increase in average on-treatment weekly number of CeD PRO improved symptom days (2.51 vs 1.99 with placebo; ANCOVA, P ¼ .034), an increase of 0.49 days/wk or 5.88 days over the treatment period. The weekly average CeD PRO abdominal domain scores were reduced 50% or more from baseline for 6 or more weeks in the larazotide acetate 0.5-mg arm (ANCOVA, P ¼ .022).
In the subset of patients reporting the highest number of GI symptomatic days scores (5-7/wk), there was a median reduction of 2.21 GI symptomatic days per week with 0.5 mg larazotide acetate, vs a median increase of 0.08 days/wk with placebo.
There was no change or worsening from baseline antitTG or anti-DGP antibody titers in any treatment group (Supplementary Figure 3) . On the Gluten-Free Diet Compliance Questionnaire, 35% and 59% of patients in the larazotide acetate 0.5-mg group reported having voluntary or accidental gluten exposure, respectively, compared with 27% and 52% in the placebo group.
Safety and Tolerability
Larazotide acetate safety and tolerability were comparable with placebo at all dose levels (Supplementary  Tables 1 and 3) . No significant changes were noted in vital signs, laboratory measures, or electrocardiograms at any larazotide acetate dose. The most frequent treatmentemergent AEs by system organ class were GI disorders and were equally frequent in all treatment groups. No significant change in iron status was noted with treatment in any of the treatment groups. There were no drug-related serious AEs.
Discussion
Larazotide acetate 0.5 mg 3 times per day improved signs and symptoms of CeD among patients with persistent symptoms despite a GFD. Conversely, higher treatment doses showed no effect. This was a large randomized controlled trial in CeD patients of a novel TJ therapeutic agent for CeD that met its primary end point. Larazotide acetate reduced GI and non-GI symptoms of CeD, decreased the weekly number of CeD PRO GI symptomatic days, increased the number of improved symptom days, and reduced abdominal domain symptom severity scores by 50% or more for at least half of the active treatment period.
In the 0.5-mg larazotide acetate group, the subset of patients reporting the highest number of GI symptomatic days scores (5-7/wk) at baseline experienced approximately 30 fewer GI symptomatic days in contrast to an increase of approximately 10 GI symptomatic days in the placebo group over the 12-week treatment period. This level of improvement is similar to what is regarded as Figure 2 . Larazotide acetate 0.5 mg 3 times per day reduced the average on-treatment weekly number of CeD PRO symptomatic days. Symptomatic days defined a priori as a day with a mean score of 3 on either the abdominal symptom or diarrhea/loose stool domains.
clinically meaningful in other conditions with episodic symptoms. [27] [28] [29] Results of this trial are consistent with previous studies, which showed a reduction in gluten-induced signs and symptoms during a gluten challenge. [14] [15] [16] An effective adjunct to the GFD has the potential to transform CeD treatment and improve the lives of patients. Practicing a strict GFD is a continuous burden and often an unsuccessful struggle for many people with CeD. [30] [31] [32] Gluten exposure is one of the common causes of ongoing or recurrent symptoms in patients with celiac disease on a GFD. The prevalence of persistent symptoms suggests that there is a substantial unmet medical need for pharmacologic approaches that can improve CeD signs and symptoms beyond what is possible with the GFD alone. [30] [31] [32] CeD PRO results show that moderate-to-severe CeD symptoms are common despite a GFD. In the 4-week placebo-run in phase, GI symptoms were reported by more than 90% of patients, and more than two thirds of patients reported tiredness and headache, suggesting that extraintestinal symptoms have a significant impact on wellbeing in patients with CeD. The placebo run-in phase showed substantial day-to-day variability in symptoms. This was not well described in the literature but it is not surprising because symptoms may be linked to gluten exposure, which is highly variable and intermittent for patients attempting a GFD. Although the observed reduction of GI symptoms may reflect nonspecific effects, this is consistent with the proposed mechanism of action of larazotide acetate of limiting gluten entry into the lamina propria by preventing intestinal TJ opening. Although larazotide acetate is a locally acting peptide restricted to the luminal surface of the small intestine, 16 the 0.5-mg dose also reduced tiredness and headache. This suggests that larazotide acetate might reduce extraintestinal symptoms, potentially through reduced local inflammation, with subsequent reduction in cytokine release.
Although we believe that this study supports the safety and efficacy of TJ modulation as a therapeutic modality in celiac disease, we do recognize potential limitations. First, direct comparison between the present study and the prior gluten challenge studies is difficult because of the lack of a dose response and the different doses used between studies. In the first study published, doses of 0.25 mg, 1 mg, 4 mg, and 8 mg 3 times per day were administered and both the 0.25-mg and 4-mg doses prevented symptoms recorded by the GSRS; only the 0.25-mg dose prevented symptoms recorded by the CeD-GSRS. 15 In the second gluten challenge study, 1 mg, 4 mg, and 8 mg 3 times per day were administered and only the 1-mg group was effective in ameliorating symptoms induced by gluten challenge measured by the CeD-GSRS. 14, 15 Although the results of this study overall are consistent with prior studies, we acknowledge that the dose range chosen was based on earlier gluten challenge data, and, for this reason, the optimal dose to study during a real-life study may not be fully understood. This inverse dose effect is not unique to larazotide acetate and has been seen for other minimally or nonabsorbed oral peptides. 33 Why higher doses appear to be less effective is unclear, but may involve peptide aggregation at higher doses, reducing activity in vivo.
Second, although prevention of an increase of celiac antibody titers despite reported gluten exposure is reassuring, we did not document a reduction in serologic titers in any treatment arm. This likely is because the majority of participants entered the study with serologic titers in the normal range, and thus were not expected to be responsive to change over the course of the real-life study. Larazotide acetate did prevent an increase of anti-tTG antibody titers during the gluten challenge, suggesting disease modification.
14 Whether larazotide acetate may result in a reduction of serologic titers over a longer time period in individuals with persistently high serologic titers will be evaluated in future studies. It also is possible that larazotide acetate may nonspecifically alleviate symptoms because celiac disease may co-exist with other common conditions including irritable bowel syndrome. Although efficacy during gluten challenge is suggestive of a mechanism of action relevant to celiac disease, the specificity of larazotide acetate for celiac disease and its utility in other conditions remains to be determined. In addition, there were few participants enrolled older than the age of 65, so efficacy in this age group cannot be inferred from the current study. Finally, histology was not an end point evaluated in this study. Although the role of histology for celiac diagnosis is clear, its utility in monitoring is controversial because there is poor correlation between symptoms, serology, histology, and quality of life in treated patients, and recent data have suggested that ongoing intestinal inflammation is not associated with significant long-term complications. 34, 35 Furthermore, although the kinetics of histologic deterioration during gluten challenge are well understood, the degree, timing, and clinical significance of improvements with adjunctive therapy in treated patients is unknown. Because of these limitations, histology may not be an appropriate primary end point for clinical trials designed to improve symptoms in patients with CeD on the GFD.
Regulating TJ activity represents a potential novel modality for treatment of diseases that involve epithelial barriers. Altered intestinal permeability is associated with many autoimmune disorders including Crohn's disease, multiple sclerosis, and type 1 diabetes. 36 The potential therapeutic activity of larazotide acetate in other disorders associated with TJ dysregulation should be explored further.
In summary, larazotide acetate 0.5 mg reduced GI and non-GI symptoms, resulting in fewer GI symptomatic days. Furthermore, in studies now including a total of 828 subjects, larazotide acetate has not been associated with safety concerns. This study represents a therapeutic trial in CeD patient to meet a primary end point of reducing symptoms in patients attempting to maintain a GFD. Larazotide acetate, the first of a novel class of agents targeting TJ regulation, thus may represent an important therapeutic option for CeD patients with persistent symptoms, although the overall efficacy and risk/benefit ratio of this therapy remain to be assessed fully. Our results contribute to a growing body of evidence of the safety and efficacy of larazotide acetate and support further investigation. NOTE. Patients were counted only once per category. A treatment-emergent AE (TEAE) was defined as an AE that occurred during the double-blind treatment phase any time between the first dose and 7 days after the last dose of study drug. TEAEs were coded using MedDRA version v.14.1.
